Physician profile
Daniela M Oneil
NPI 1902267909
$2,004.82
in general payments reported to CMS, 2019-2025
22 companies · $493 in 2025
The $493 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $102 · 2022: $398 · 2023: $375 · 2024: $637 · 2025: $493.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,505.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,504.56 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $510.06 | 2021-2025 | Wegovy, Rybelsus, Ozempic |
| Lilly USA, LLC | $326.46 | 2021-2025 | Mounjaro, Zepbound, Jardiance |
| Abbvie INC. | $254.58 | 2021-2025 | |
| Exact Sciences Corporation | $163.14 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Otsuka America Pharmaceutical, INC. | $115.88 | 2023-2024 | Rexulti, Nuedexta |
| Astrazeneca Pharmaceuticals LP | $95.99 | 2024-2025 | Airsupra, Farxiga |
| Pfizer INC. | $71.83 | 2024-2025 | |
| Amgen INC. | $63.79 | 2021-2024 | Repatha, Otezla |
| Boehringer Ingelheim Pharmaceuticals, INC. | $61.50 | 2021-2023 | Jardiance |
| Merck Sharp & Dohme LLC | $58.26 | 2022-2025 | Gardasil 9, Capvaxive |
| Bausch Health US, LLC | $46.17 | 2025 | Wellbutrin |
| Axsome Therapeutics, INC. | $45.05 | 2025 | Auvelity |
| Glaxosmithkline, LLC. | $34.18 | 2023-2025 | Shingrix, Arexvy |
| Phathom Pharmaceuticals, INC. | $23.34 | 2024 | Voquezna |
| Edwards Lifesciences Corporation | $19.30 | 2022 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Cequr Corporation | $18.73 | 2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $17.84 | 2024 | Xifaxan |
| Eisai INC. | $17.73 | 2022 | |
| Scilex Pharmaceuticals INC. | $15.68 | 2022 | |
| Corcept Therapeutics | $15.57 | 2024 | Korlym |
| Bayer Healthcare Pharmaceuticals INC. | $15.00 | 2024 | |
| Dynavax Technologies Corporation | $14.74 | 2023 | Heplisav-B |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daniela Oneil listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.